Literature DB >> 1838850

Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease.

E Masliah1, M Mallory, L Hansen, M Alford, T Albright, R Terry, P Shapiro, M Sundsmo, T Saitoh.   

Abstract

Both protein kinases and phosphoprotein phosphatases are important components of signal transduction systems in cells. Recent studies in Alzheimer's disease (AD) have shown abnormal protein phosphorylation in the cortex suggesting an alteration in these enzymes. In the present study, an antibody against CD45 was used to analyze the status of this protein phosphotyrosine phosphatase in AD. We studied and quantified the immunohistochemical and immunochemical distribution of this integral membrane protein in control and AD brain. We found that anti-CD45 immunostained the great majority of microglia, both resting and activated. These cells were Ricinus communis agglutinin I positive and glial fibrillary acidic protein and neurofilament negative. The AD frontal cortex showed a 35% (P less than 0.01) increase in the number of anti-CD45 immunoreactive microglia as compared with controls. These results were consistent with the immunoblot quantification of CD45 immunoreactivity following native gel electrophoresis. In AD, 30% of the CD45-immunostained microglia were clustered in the neuritic plaques (about six per plaque) while the remaining 70% were scattered in the neuropil. The AD hippocampus showed an increase in CD45-immunoreactive microglia in the molecular layer of the dentate gyrus. At the ultrastructural level, CD45 immunoreactivity was localized exclusively to the plasma membrane of the microglia. The presence of the anti-CD45 immunoreactivity in microglia suggests the possibility that they may require the presence of CD45 as a cell surface receptor which may regulate cell function through modulation of intracellular signaling.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838850     DOI: 10.1007/bf00294425

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  41 in total

1.  Cholinergic sprouting in the hippocampus: a proposed role for IL-1.

Authors:  A M Fagan; F H Gage
Journal:  Exp Neurol       Date:  1990-10       Impact factor: 5.330

2.  Decreased levels of protein kinase C in Alzheimer brain.

Authors:  G Cole; K R Dobkins; L A Hansen; R D Terry; T Saitoh
Journal:  Brain Res       Date:  1988-06-14       Impact factor: 3.252

Review 3.  Functional plasticity of microglia: a review.

Authors:  W J Streit; M B Graeber; G W Kreutzberg
Journal:  Glia       Date:  1988       Impact factor: 7.452

4.  Alz-50 recognizes a phosphorylated epitope of tau protein.

Authors:  K Uéda; E Masliah; T Saitoh; S L Bakalis; H Scoble; K S Kosik
Journal:  J Neurosci       Date:  1990-10       Impact factor: 6.167

5.  Altered protein tyrosine phosphorylation in Alzheimer's disease.

Authors:  I P Shapiro; E Masliah; T Saitoh
Journal:  J Neurochem       Date:  1991-04       Impact factor: 5.372

6.  Aberrant casein kinase II in Alzheimer's disease.

Authors:  D S Iimoto; E Masliah; R DeTeresa; R D Terry; T Saitoh
Journal:  Brain Res       Date:  1990-01-22       Impact factor: 3.252

7.  Evidence for a haematogenous origin of some of the macrophages appearing in the spinal cord of the rat after dorsal rhizotomy.

Authors:  E A Ling
Journal:  J Anat       Date:  1979-01       Impact factor: 2.610

8.  A monoclonal antibody useful for the differential diagnosis between malignant lymphoma and nonhematopoietic neoplasms.

Authors:  H Battifora; I S Trowbridge
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

9.  Brain microglia constitutively express beta-2 integrins.

Authors:  H Akiyama; P L McGeer
Journal:  J Neuroimmunol       Date:  1990-11       Impact factor: 3.478

10.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  39 in total

1.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

3.  Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer's disease and multiple sclerosis.

Authors:  P Hemachandra Reddy; Maria Manczak; Wei Zhao; Kazuhiro Nakamura; Christopher Bebbington; Geoffrey Yarranton; Peizhong Mao
Journal:  J Neurochem       Date:  2009-10-14       Impact factor: 5.372

4.  Remembering Robert D. Terry at a Time of Change in the World of Alzheimer's Disease.

Authors:  Nickolas Terry; Alberto Masliah; Cassia Overk; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 5.  Microglia and inflammation: conspiracy, controversy or control?

Authors:  Adelaide Fernandes; Leonor Miller-Fleming; Teresa F Pais
Journal:  Cell Mol Life Sci       Date:  2014-07-10       Impact factor: 9.261

6.  Anti-CD45RO suppresses human immunodeficiency virus type 1 replication in microglia: role of Hck tyrosine kinase and implications for AIDS dementia.

Authors:  Mee-Ohk Kim; Hyeon-Sook Suh; Qiusheng Si; Bruce I Terman; Sunhee C Lee
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss.

Authors:  G William Rebeck; Hyang-Sook Hoe; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

Review 8.  Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy.

Authors:  L W Jin; T Saitoh
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

9.  A phenotypic change but not proliferation underlies glial responses in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Teresa Gómez-Isla; John H Growdon; Matthew P Frosch; Bradley T Hyman
Journal:  Am J Pathol       Date:  2013-04-18       Impact factor: 4.307

Review 10.  APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.

Authors:  Leslie Crews; Edward Rockenstein; Eliezer Masliah
Journal:  Brain Struct Funct       Date:  2009-11-29       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.